Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply

Medema, Jan Paul; Zoellner, York; Ryan, James A.; Palache, Abraham

doi:10.1016/j.virusres.2004.02.006

Cited by 27 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Article abstracts were read and evaluated on their appropriateness for the review, and 16 articles were read in total. Of these, 12 articles were judged to adhere to the aforementioned inclusion criteria [14][15][16][17][18][19][20][21][22][23][24][25] and four were discarded from this review [26][27][28][29]. With one exception ( [22]), all reviewed articles were published in 2004 or later.…”

Section: Methodsmentioning

confidence: 99%

“…Cost effective to stockpile for treating therapeutically [20] Doyle et al Cell culture-based vaccine manufacture prevents more influenza cases than an eggbased vaccine [21] Lee et al …”

Section: Cost Per Life-year Gainedmentioning

confidence: 99%

“…In the remaining studies, the cost-effectiveness calculations were based on static models (e.g., decision trees or similar constructions) [14,15,17,18,[21][22][23]25].…”

Section: Reviewmentioning

confidence: 99%

See 2 more Smart Citations

Mitigation of pandemic influenza: review of cost–effectiveness studies

Lugnér¹,

Postma

2009

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

We conducted a review of economic evaluations of pandemic influenza control measures. In the studies found, we detected various interventions being investigated: antiviral stockpiling and treatment, prophylaxis, vaccination, school closure and restricting international travel. Cost-effectiveness varied but often showed potentials for the favorable economic profiles of these measures. Both static and dynamic models were used. We conclude that the choice of an appropriate model - in particular, a dynamic model - is crucial to arrive at valid cost-effectiveness ratios. Yet, of the economic evaluations considered here, only a few were based on dynamic modeling. We recommend that further research is directed toward linking dynamic epidemiological models for pandemic spread with economic outcomes by considering the full impacts on national economies, including direct, indirect, medical and nonmedical costs.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Cost effective to stockpile for treating therapeutically [20] Doyle et al Cell culture-based vaccine manufacture prevents more influenza cases than an eggbased vaccine [21] Lee et al …”

Section: Cost Per Life-year Gainedmentioning

confidence: 99%

See 1 more Smart Citation

Mitigation of pandemic influenza: review of cost–effectiveness studies

Lugnér¹,

Postma

2009

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…9 The biggest concern with a pandemic is inadequate product supply capacity, owing to the inflexibility and poor responsiveness of current egg-based vaccine manufacture systems. The logistics of egg preparation means that approximately a year is needed for production, and there is concern over the availability of a sufficient quantity of eggs outside the planned period.…”

Section: Vaccine Production: Egg-based Versus Cell Culture Flumentioning

confidence: 99%

“…The logistics of egg preparation means that approximately a year is needed for production, and there is concern over the availability of a sufficient quantity of eggs outside the planned period. 9 The potential impact of this inflexibility was recently highlighted when contamination issues forced British regulators to revoke Chiron's licence to manufacture flu vaccines in 2004, which halved the USA's supply of vaccines. Furthermore, provisions for the annual influenza epidemics cannot necessarily be extrapolated to a pandemic.…”

Section: Vaccine Production: Egg-based Versus Cell Culture Flumentioning

confidence: 99%

Growth drivers and resistors of the influenza market: The importance of cell culture flu

Belsey¹,

Evans²,

Pavlou³

et al. 2006

JCB

View full text Add to dashboard Cite

Following flu vaccine manufacturing and supply issues in the USA and the global threat of an avian flu pandemic, the flu market is attracting considerable interest. This market was worth approximately US$1.1bn in 2004, and it is expected to grow to US$3.1bn by 2010: a compound annual growth rate of 17.1 per cent. To capitalise on this explosive growth rate, flu vaccine manufacturers should position their products towards combating the avian flu pandemic threat. However, there are a number of challenges associated with producing avian flu vaccines using egg-based manufacture systems: currently the dominant vaccine production technique. In the current paper, Datamonitor's infectious disease analysis team argues the case for the potential transformation of the flu market by governmental initiatives, and specifically on the role of these initiatives in driving cell culture flu manufacture as part of pandemic preparedness plans.

show abstract

Modeling and Simulation in Terror Medicine

Hirshberg

Mattox

Essentials of Terror Medicine

View full text Add to dashboard Cite

Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply

Cited by 27 publications

References 9 publications

Mitigation of pandemic influenza: review of cost–effectiveness studies

Mitigation of pandemic influenza: review of cost–effectiveness studies

Growth drivers and resistors of the influenza market: The importance of cell culture flu

Modeling and Simulation in Terror Medicine

Contact Info

Product

Resources

About